Unreliable usage of a single influenza virus IgM antibody assay in influenza-like illness: A retrospective study of the 2016–2018 flu epidemic

Yao, Yao; Zhao, Zhen; Song, Wenqi; Li, Runqing; Zhu, Dong; Qin, Kun; Zhao, Xing‐Ming

doi:10.1371/journal.pone.0215514

Cited by 10 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rapid influenza diagnostic test was performed using Clearview Exact Influenza A&B (ABON Biopharm Co., Ltd, Hangzhou, China) following the manufacturer’s instructions. The test strip was coated with antibodies against nucleoproteins of influenza A and B virus at different positions to distinguish antigens between influenza A and B virus (Yao et al 2019).…”

Section: Methodsmentioning

confidence: 99%

Evaluation of a novel micro/nanofluidic chip platform for the detection of influenza A and B virus in patients with influenza-like illness

Gai²,

Zhu

et al. 2019

AMB Expr

View full text Add to dashboard Cite

We introduced a novel micro/nanofluidic chip platform (MNCP), which is based on an isothermal nucleic acid amplification method. This study aimed to evaluate the MNCP method for influenza A and B viruses detecting and subtyping using throat swab samples from patients with influenza-like illness (ILI). A total of 266 throat swab samples from 266 non-repeated patients with ILI were tested for influenza A and B viruses using three methods, MNCP, a rapid influenza diagnostic test (RIDT), and real-time reverse transcription polymerase chain reaction (rRT-PCR). The results of MNCP were compared to those obtained by rRT-PCR and RIDT and the performance of MNCP was further evaluated. Compared with rRT-PCR results, the rates of sensitivity, specificity, overall concordance, and the kappa value of MNCP were 98.89%, 96.97%, 97.65%, and 0.95 for influenza A virus; 94.95%, 99.38%, 97.68%, and 0.95 for influenza B virus, respectively. Subtypes of influenza A viruses, e.g., A(H1N1)pdm09, A(H3N2), and A(not subtyped), and influenza B viruses could be distinguished in one MNCP assay within 1 h. Compared with rRT-PCR and MNCP, RIDT showed poor clinical sensitivity for influenza virus detection. This study showed MNCP is rapid, sensitive and versatile detecting system with potential for clinical application in pathogen diagnosis for patients with ILI.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of a novel micro/nanofluidic chip platform for the detection of influenza A and B virus in patients with influenza-like illness

Gai²,

Zhu

et al. 2019

AMB Expr

View full text Add to dashboard Cite

show abstract

“…The positive rate of IgM antibody might varies in different virus. The low positive rate of IgM antibody also exists in children infected with influenza A, but it can reach 41–51% after influenza B infection ( 18 ). Therefore, it is necessary to collect large samples and regular data with dense detection time-points to explore the positive results of IgM antibody.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Changes on Clinical Features in 28 Children With COVID-19 in Shenzhen, China

Liao

Liu

et al. 2020

Front. Med.

View full text Add to dashboard Cite

Objective: To investigate the clinical characteristics of children with coronavirus disease 2019 (COVID-19) and identify the occurrence of viral shedding of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) during follow-up. Methods: We retrospectively retrieved data from pediatric patients with COVID-19 from the Shenzhen Third People's Hospital in China. The dynamics of SARS-CoV-2 and antibodies against SARS-CoV-2 were analyzed during hospitalization and after discharge. Results: From January 23 to March 15, 2020, a total of 28 pediatric patients were diagnosed with COVID-19 and were followed for at least 1 month. The median age was 7 years (IQR 3.5–10) and none of the children progressed to severe COVID-19 during hospitalization. Ten patients tested positive for SARS-CoV-2 1 month after discharge while four patients tested positive during the 2nd month after discharge. Only three of 12 children showed detectable immunoglobulin-M (IgM) on day 5, 18, and 21 after illness onset, respectively. Conclusions: COVID-19 disease was relatively mild among children while a number did test positive after discharge from the hospital. Public health initiatives should thus adapt control measures targeted toward children.

show abstract

“…ILI may occur in population as co-infection of SARS-CoV-2 and in uenza virus during the pandemic. Sustained surveillance of ILI has been implemented by Centers for Disease Control and Prevention (CDC) [7][8][9] and the co-infection of in uenza viruses and SARS-CoV-2 was possible at 2019-2020 in uenza season [2,10]. According to previous study, in uenza virus-speci c antibody responses following in uenza infection rises in HA-speci c serum IgM (86 to 94%) antibodies after primary in uenza virus infection in adults [11].…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: A retrospective cohort study from Wuhan, China

Tong

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundCoronavirus disease 2019 (COVID-19) is an emerging infectious disease that rapidly spreads worldwide and co-infection of COVID-19 and influenza may occur in some cases. We aimed to describe clinical features and outcomes of severe COVID-19 patients with co-infection of influenza virus.MethodsRetrospective cohort study was performed and a total of 140 patients with severe COVID-19 were enrolled in designated wards of Sino-French New City Branch of Tongji Hospital between Feb 8th and March 15th in Wuhan city, Hubei province, China. The demographic, clinical features, laboratory indices, treatment and outcomes of these patients were collected.ResultsOf 140 severe COVID-19 hospitalized patients, including 73 patients (52.14%) with median age 62 years were influenza virus IgM-positive and 67 patients (47.86%) with median age 66 years were influenza virus IgM-negative. 76 (54.4%) of severe COVID-19 patients were males. Chronic comorbidities consisting mainly of hypertension (45.3%), diabetes (15.8%), chronic respiratory disease (7.2%), cardiovascular disease (5.8%), malignancy (4.3%) and chronic kidney disease (2.2%). Clinical features, including fever (≥38°C), chill, cough, chest pain, dyspnea, diarrhea and fatigue or myalgia were collected. Fatigue or myalgia was less found in COVID-19 patients with IgM-positive (33.3% vs 50/7%, P = 0.0375). Higher proportion of prolonged activated partial thromboplastin time (APTT) > 42 s was observed in COVID-19 patients with influenza virus IgM-negative (43.8% vs 23.6%, P = 0.0127). Severe COVID-19 Patients with influenza virus IgM positive have a higher cumulative survivor rate than that of patients with influenza virus IgM negative (Log-rank P= 0.0308). Considering age is a potential confounding variable, difference in age was adjusted between different influenza virus IgM status groups, the HR was 0.29 (95% CI, 0.081-1.100). Similarly, difference in gender was adjusted as above, the HR was 0.262 (95% CI, 0.072-0.952) in the COX regression model.ConclusionsInfluenza virus IgM positive may be associated with decreasing in-hospital death.

show abstract

Unreliable usage of a single influenza virus IgM antibody assay in influenza-like illness: A retrospective study of the 2016–2018 flu epidemic

Cited by 10 publications

References 33 publications

Evaluation of a novel micro/nanofluidic chip platform for the detection of influenza A and B virus in patients with influenza-like illness

Evaluation of a novel micro/nanofluidic chip platform for the detection of influenza A and B virus in patients with influenza-like illness

Longitudinal Changes on Clinical Features in 28 Children With COVID-19 in Shenzhen, China

Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: A retrospective cohort study from Wuhan, China

Contact Info

Product

Resources

About